CompletedPhase 2NCT00994929
Efficacy and Safety of IL-11 in DDAVP Unresponsive
Studying Mild hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pittsburgh
- Principal Investigator
- Margaret V. Ragni, MD, MPH, mdUniversity of Pittsburgh
- Intervention
- Neumega (Oprelvekin, Interleukin 11, IL-11)(biological)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2012
Study locations (1)
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00994929 on ClinicalTrials.gov